Literature DB >> 1101599

Acute effects of exogenous growth hormone in man: time- and dose-bound modification of glucose tolerance and glucose-induced insulin release.

U Adamson, E Cerasi.   

Abstract

The time and dose dependency of the effects of a 30-min long iv infusion of human growth hormone (GH) on glucose tolerance and glucose-stimulated insulin release was investigated in 19 healthy subjects. Glucose tolerance deteriorated immediately following GH, and the k-value continued to decrease up to 300 min later. A small but significant reduction of glucose tolerance persisted 24 h after GH administration. Significant deterioration of glucose tolerance was observed with the smallest GH dose used (5 mug per kg body weight), increasing the amount of the hormone having no further major influence. Glucose-stimulated insulin release was significantly inhibited 1 h after administration of a relatively high GH dose (40 mug per kg), both if expressed as mean plasma insulin levels, or as insulin release per magnitude of glucose stimulation (insulinogenic index). In the majority of subjects, insulin release was inhibited also by lower GH doses (5-20 mug GH per kg). However, the mean change with these doses was not statistically significant. The inhibitory effect of GH on insulin secretion seemed to have a duration of several hours. Five hours, but not 24 h, after GH administration (10 mug GH per kg) insulin release was still significantly suppressed. It is suggested that the initial effect of GH on pancreatic beta cells may be inhibition of insulin release, in contrast with the enhancement of insulin secretion observed during chronic administration of GH.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1101599     DOI: 10.1530/acta.0.0800247

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  7 in total

1.  Comment to: Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B (2005) The Somogyi phenomenon revisited using continuous glucose monitoring in daily life. Diabetologia 48:2437-2438.

Authors:  I Iseda; P E Lins; U Adamson; M Kollind
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

2.  Prolonged insulin resistance following insulin-induced hypoglycaemia.

Authors:  J N Clore; J R Brennan; S P Gebhart; H H Newsome; J E Nestler; W G Blackard
Journal:  Diabetologia       Date:  1987-11       Impact factor: 10.122

3.  Physiologic concentrations of exogenously infused ghrelin reduces insulin secretion without affecting insulin sensitivity in healthy humans.

Authors:  Jenny Tong; Ronald L Prigeon; Harold W Davis; Martin Bidlingmaier; Matthias H Tschöp; David D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2013-04-15       Impact factor: 5.958

4.  Ghrelin stimulation of growth hormone isoforms: parallel secretion of total and 20-kDa growth hormone and relation to insulin sensitivity in healthy humans.

Authors:  Jenny Tong; David D'Alessio; Juliane Ramisch; Harold W Davis; Elizabeth Stambrook; Matthias H Tschöp; Martin Bidlingmaier
Journal:  J Clin Endocrinol Metab       Date:  2012-06-28       Impact factor: 5.958

5.  Characterization of the insulin-antagonistic effect of growth hormone in man.

Authors:  J Fowelin; S Attvall; H von Schenck; U Smith; I Lager
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

6.  Previous exposure to glucose enhances insulin and suppresses glucagon responses to arginine in man.

Authors:  U Adamson; V Grill; S Efendić
Journal:  Acta Diabetol Lat       Date:  1981 Apr-Jun

7.  Effect of growth hormone on oral glucose tolerance and circulating metabolic fuels in man.

Authors:  R S Sherwin; G A Schulman; R Hendler; M Walesky; A Belous; W Tamborlane
Journal:  Diabetologia       Date:  1983-03       Impact factor: 10.122

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.